ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LGVN / forecast
SCNX (28) PCSA (39) ADXN (48) GELS (54) ⌘ Pro Terminal →

Longeveron Inc. (Class A) (LGVN) 12-Month Stock Forecast & Price Target Cone

$1.71 +2.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.71

Longeveron Inc. (Class A) (LGVN) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $5.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LGVN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LGVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Longeveron Inc. (Class A) (NASDAQ: LGVN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.71 (+2.40% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LGVN ranks #893 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LGVN compare to SCNX and PCSA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGVN carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 67.0%, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, LGVN leads on earnings multiple (N/A) while LGVN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LGVN?
▼

Per LGVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001721484), Longeveron Inc. (Class A) generated $1.2M in revenue (-49.9% YoY), -$22.7M in net income, and -$18.9M in free cash flow against $10.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.71 (+0.24%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510027
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (3)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-14% Base Target
$13 Bull$1 Base$1 Bear
📬 FREE LGVN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LGVN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (27/100 Composite)
🔍 WHY LGVN SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 67% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
35
Grade E$2.15-30.2% Next Q
Q2 (-2Q)
32
Grade E$1.50+15.3% Next Q
Q3 (-1Q)
30
Grade E$1.73-1.2% Next Q
Current
27
Grade E$1.71-10.3% Hist 90D α
Trajectory: E (35) → E (27)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LGVN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LGVN currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.63) and Max Pain ($1.80) forces dealer call-delta covering toward $12.92.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LGVN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LGVN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 27%NO 73%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your LGVN Position Size: $10,000

Shares at $1.71: 5848.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1.15
$6,725
$-3,275 (-32.7%)
12M Consensus BaseTarget $1.47
$8,596
$-1,404 (-14.0%)
12M Bull Case BreakoutTarget $12.92
$75,556
+$65,556 (+655.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$274%A
Goldman SachsSector Coverage LeadUNDERPERFORM$1269%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LGVN)

  • ✓Walkthrough of LGVN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LGVN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.19%📐 HORIZONTAL RANGE
2026-11-03O $1.75H $1.75L $1.67C $1.71VOL 80.8K
RES: $8.83SUP: $0.77SMA50: $3.63SMA200: $6.60
$10.01$7.65$5.29$2.94$0.58RES $8.83SUP $0.77$1.712026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LGVN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LGVN Butterfly Map → + Track LGVN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -49.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LGVN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LGVN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LGVN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LGVN)

Health Care Rank #893 of 1015 ⚔️ SCNX vs LGVN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LGVN vs. SCNX, PCSA, ADXN, GELS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Longeveron Inc. (Class A) (LGVN) ranks #893 by composite RQD confidence (27/100, grade E) and #933 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, LGVN leads on earnings valuation at N/A trailing P/E, while LGVN leads on capital efficiency and profitability with -35.0% ROIC and 67.0% gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 54/100 (D+) compared with LGVN at 27/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LGVN ACTIVE
Longeveron Inc. (Class A)
E 27/100 — 67.0% -35.0% +2.40% $5.3M Benchmark Subject
SCNX
Scienture Holdings Inc.
E 28/100 — 76.8% -35.0% +0.31% $5.3M /scnx-vs-lgvn →
PCSA
Processa Pharmaceuticals Inc.
D- 39/100 — — -35.0% -2.12% $5.3M /pcsa-vs-lgvn →
ADXN
Addex Therapeutics Ltd
D 48/100 — — — -3.24% $5.3M /adxn-vs-lgvn →
GELS
Gelteq Limited
D+ 54/100 — — — -0.10% $5.2M /gels-vs-lgvn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001721484 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Longeveron Inc. (Class A) (LGVN) reported GAAP revenue of $1.2M (-49.9% vs. FY2024 revenue of $2.4M , and +69.1% cumulative change since FY2023) , GAAP net income of -$22.7M, operating cash flow of -$18.6M, and free cash flow of -$18.9M (-30.1% YoY). On the balance sheet, LGVN closed FY2025 with $10.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.2M -$22.7M -$18.6M -$18.9M $10.3M —
FY2024 (FY) 2024-12-31 $2.4M -$16.0M -$13.9M -$14.5M $25.6M —
FY2023 (FY) 2023-12-31 $709.0K -$21.4M -$19.0M -$19.0M — —

3. LGVN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LGVN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Longeveron Inc. (Class A) (NASDAQ: LGVN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $1.71 (+2.40% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LGVN ranks #893 in composite RQD confidence.

How does LGVN compare to SCNX and PCSA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LGVN carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 67.0%, and ROIC of -35.0%. By comparison, SCNX (Scienture Holdings Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M) and PCSA (Processa Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $5.3M). Among the 5-stock peer group, LGVN leads on earnings multiple (N/A) while LGVN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LGVN?

Per LGVN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001721484), Longeveron Inc. (Class A) generated $1.2M in revenue (-49.9% YoY), -$22.7M in net income, and -$18.9M in free cash flow against $10.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LGVN trading relative to its 50-day, 200-day, and 52-week technical levels?

LGVN last traded at $1.71 (+2.40% on volume of 63,492 shares), positioning the stock -52.89% below its 50-day simple moving average ($3.63) and -74.09% below its 200-day simple moving average ($6.60). Across its 52-week range of $1.31 to $12.30, LGVN sits at the 3.6% percentile with a 14-day RSI of 32.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.50 to $1.92).

Direct Sub-Reports: LGVN RQD Cockpit LGVN 12M Forecast LGVN Earnings & Move LGVN Dividends & DRIP LGVN Insiders & 13F LGVN Whale Options LGVN Profit Sankey LGVN News & Why
ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

LGVN — Longeveron Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Longeveron Inc. (Class A) (LGVN) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.71 (+2.40% 1D, market capitalization $5.3M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 67.0%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Longeveron Inc. (Class A) (LGVN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — for product details, customer base, or specific revenue mechanics. FY 2025 revenue was $1.2M against FY 2024 revenue of $2.4M and FY 2023 revenue of $0.7M. Gross margin is 67%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Longeveron Inc. (Class A) (LGVN) reported $1.2M in annual revenue (up from $2.4M in FY2024, -49.9% YoY) and -$22.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($709.0K revenue, -$21.4M net income) through FY2025, LGVN scaled operating cash flow to -$18.6M and free cash flow to -$18.9M, backed by $10.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.31 – $12.30 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LGVN carries a macro regime beta of 1.00 and gross margin of 67.0%.

  • Key Question #1: Can LGVN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.2M and free cash flow of -$18.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LGVN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LGVN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Longeveron Inc. (Class A) (LGVN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LGVN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LGVN Bull vs. Bear Conversation Board — What's Your Call at $1.71?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LGVN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LGVN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $1.94 (+16.2%)
📌 Pinned Debate

Revenue grew from $0.7M in FY 2023 to $2.4M in FY 2024 before declining to $1.2M in FY 2025, and gross margin is 67%.

Picked up a starter position in LGVN in my $100K Virtual Cash book at $1.67. Revenue grew from $0.7M in FY 2023 to $2.4M in FY 2024 before declining to $1.2M in FY 2025, and gross margin is 67%.. Trading inside a $1.31–$12.30 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

RetailWhale_TX 🐂 BULL

Both sides have a point here — LGVN's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $1.44 (-13.8%)
Spot @ $1.67

Operating margin of -60%, ROIC of -35%, and cash falling from $19.2M to $4.7M raise near-term funding and solvency concerns.

Fading this rally in LGVN at $1.67. Operating margin of -60%, ROIC of -35%, and cash falling from $19.2M to $4.7M raise near-term funding and solvency concerns.. With a beta of 1.0 and the stock sitting at $1.67 (52-wk range $1.31–$12.30), the easy multiple expansion is already priced in.

LIVE TAPE